<DOC>
	<DOCNO>NCT00585195</DOCNO>
	<brief_summary>PF-02341066 may work cancer block cell growth , migration invasion tumor cell . PF-02341066 new class drug call c-Met/Hepatocyte growth factor receptor tyrosine kinase inhibitor . This compound also inhibitor anaplastic lymphoma kinase ( call ALK ) tyrosine kinase ROS receptor tyrosine kinases . This research study first time PF-02341066 give people . PF-02341066 take mouth daily .</brief_summary>
	<brief_title>A Study Of Oral PF-02341066 , A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor , In Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>Advanced malignancy ( except leukemia ) , histologically proven diagnosis ; Histologically confirm advanced malignancy know sensitive PF03241066 inhibition , e.g . ALK , cMET ROS Solid tumor must measurable disease ( Recommended Phase 2 Dose Cohort patient nonmeasurable disease may enter casebycase basis ) ; require DDI substudies . Adequate blood cell count , kidney function , liver function Eastern Cooperative Oncology Group ( ECOG ) score 0 1 ( Recommended Phase 2 Cohort , ECOG score 2 may allow casebycase basis ) Major surgery , radiation therapy anticancer therapy within 2 4 week start study treatment , depend patient cohort Prior stem cell transplant except patient neuroblastoma , lymphoma myeloma Active unstable cardiac disease heart attack within 3 month start study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Crizotinib</keyword>
	<keyword>dose-finding</keyword>
	<keyword>drug-drug interaction</keyword>
	<keyword>ALK rearrangement</keyword>
	<keyword>c-Met mutation amplification</keyword>
	<keyword>c-Met dependent tumor</keyword>
	<keyword>ROS1 rearrangement</keyword>
	<keyword>c-Met exon 14 deletion</keyword>
	<keyword>c-Met exon 14 skipping</keyword>
	<keyword>c-Met exon 14 alteration</keyword>
</DOC>